Treatment with ibuprofen and other non-steroidal anti-inflammatory dru
gs (NSAIDS) has been reported to decrease the incidence as well as slo
w down the progression of Alzheimer's disease. Understanding the mecha
nism of this therapeutic effect would provide a target for development
of drugs which may be devoid of side effects observed with NSAIDs. In
addition to inhibiting cyclooxygenase (COX), the NSAIDs have recently
been shown to decrease inducible nitric oxide synthase (iNOS) activit
y. Ibuprofen and other NSAIDs had no direct effect on catalytic activi
ty of iNOS, but decreased levels of iNOS mRNA. The mechanism of action
of ibuprofen on reduction of iNOS activity has been further investiga
ted in the present study using rat primary cerebellar glial cell cultu
res. In addition; the effect of ibuprofen on COX mRNA expression and p
rostaglandin information was also studied. Glial cells treated with E.
coli lipopolysaccharide (LPS) and interferon gamma (INF gamma) for 16
h expressed iNOS and COX. Ibuprofen did not directly inhibit iNOS act
ivity. However, when ibuprofen was incubated at the same time with LPS
and INF gamma for 16 h, enzyme activity was reduced, with an IC50 of
0.76 mM. Ibuprofen concentration-dependently decreased iNOS mRNA level
s, with an IC50 >2 mM. Thus, there was no correlation between decrease
in iNOS activity and reduction in iNOS mRNA levels. Ibuprofen decreas
ed iNOS protein levels, as determined by Western blot, with an IC50 of
0.89 mM. The data suggest that the reduction in iNOS activity by ibup
rofen is due io inhibition of post-transcriptional processing of this
enzyme. Ibuprofen had no effect on constitutive COX (COX-1) or inducib
le COX (COX-2) mRNA expression. However, ibuprofen inhibited PGE(2) fo
rmation with an IC50 of 0.86 mM. The anti-inflammatory actions of ibup
rofen have been related to inhibition of COX and, subsequently, reduci
ng prostaglandin formation. Since the potency of ibuprofen for inhibit
ion of PGE(2) formation and reduction in iNOS activity are similar, it
is suggested that. at therapeutically effective doses, a decrease in
iNOS activity may also occur in vivo. Therefore, reduction in iNOS pro
tein levels in the brain may have a role in preserving the integrity o
f neurons in individuals susceptible to Alzheimer's disease. (C) 1997
Elsevier Science B.V.